{"id":746057,"date":"2019-04-10T05:45:00","date_gmt":"2019-04-10T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/"},"modified":"2025-05-12T08:58:13","modified_gmt":"2025-05-12T12:58:13","slug":"lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/","title":{"rendered":"LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       AstraZeneca and Merck\u2019s LYNPARZA Reduced the Risk of Disease        Progression or Death by 42 Percent Versus Chemotherapy in Phase 3        OlympiAD Trial     <\/p>\n<p class=\"bwalignc\">       First PARP Inhibitor Approved in the EU for This Indication and Third        EU Approval for LYNPARZA     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United<br \/>\n      States and Canada, today announced the European Commission has approved<br \/>\n      LYNPARZA as a monotherapy for the treatment of adult patients with<br \/>\n      germline <i>BRCA<\/i>1\/2-mutations (g<i>BRCA<\/i>m), and who have human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative locally advanced or<br \/>\n      metastatic breast cancer.\n    <\/p>\n<p>\n      Under the licensed indication, patients should have previously been<br \/>\n      treated with an anthracycline and a taxane in the (neo)adjuvant or<br \/>\n      metastatic setting unless they were unsuitable for these treatments.<br \/>\n      Patients with hormone receptor (HR)-positive breast cancer should also<br \/>\n      have progressed on or after prior endocrine therapy or be considered<br \/>\n      unsuitable for endocrine therapy.\n    <\/p>\n<p>\n      Dave Fredrickson, executive vice president, oncology, AstraZeneca, said,<br \/>\n      \u201cWith this approval, LYNPARZA provides patients throughout the EU with a<br \/>\n      targeted and oral chemotherapy-free treatment option for a<br \/>\n      difficult-to-treat cancer. It also reinforces the importance of testing<br \/>\n      for biomarkers, including <i>BRCA<\/i>, hormone receptor and HER2<br \/>\n      expression, helping physicians to make the most informed treatment<br \/>\n      decisions for patients.\u201d\n    <\/p>\n<p>\n      Dr. Roy Baynes, senior vice president and head of global clinical<br \/>\n      development, chief medical officer, Merck Research Laboratories, said,<br \/>\n      \u201cIn the OlympiAD trial, which supported this approval, LYNPARZA<br \/>\n      demonstrated a meaningful improvement in progression-free survival<br \/>\n      compared to chemotherapy in patients with germline <i>BRCA<\/i>-mutated<br \/>\n      metastatic breast cancer. We look forward to making this new option<br \/>\n      available across the EU, where we hope it will improve outcomes for many<br \/>\n      patients.\u201d\n    <\/p>\n<p>\n      The approval was based on data from the randomized, open-label, Phase 3<br \/>\n      OlympiAD trial which investigated LYNPARZA versus physician\u2019s choice of<br \/>\n      chemotherapy (capecitabine, eribulin or vinorelbine). In the trial,<br \/>\n      LYNPARZA provided patients with a statistically significant median<br \/>\n      progression-free survival improvement of 2.8 months (7.0 months for<br \/>\n      LYNPARZA vs 4.2 months for chemotherapy). Patients taking LYNPARZA<br \/>\n      experienced an objective response rate (ORR) of 52 percent, which was<br \/>\n      double the ORR for those in the chemotherapy arm (23%).\n    <\/p>\n<p>\n      The most common adverse reactions (\u226520%) in the OlympiAD trial of<br \/>\n      patients who received LYNPARZA were nausea (58%), anemia (40%), fatigue<br \/>\n      (including asthenia) (37%), vomiting (30%), neutropenia (27%),<br \/>\n      respiratory tract infection (27%), leukopenia (25%), diarrhea (21%) and<br \/>\n      headache (20%). The percentage of patients who discontinued treatment in<br \/>\n      the LYNPARZA arm was five percent versus eight percent in the<br \/>\n      chemotherapy arm.\n    <\/p>\n<p>\n      This is the third indication for LYNPARZA in the EU, and AstraZeneca and<br \/>\n      Merck are working together to deliver LYNPARZA as quickly as possible to<br \/>\n      more patients across multiple settings. LYNPARZA has a broad clinical<br \/>\n      development program, including the ongoing Phase 3 trial OlympiA which<br \/>\n      is evaluating LYNPARZA as an adjuvant treatment in patients with g<i>BRCA<\/i>m<br \/>\n      HER2-negative breast cancer.\n    <\/p>\n<p>\n      <b>IMPORTANT SAFETY INFORMATION<\/b>\n    <\/p>\n<p>\n      <b>CONTRAINDICATIONS<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>WARNINGS AND PRECAUTIONS<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML): <\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some also had a<br \/>\n      history of more than one primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment.\n    <\/p>\n<p>\n      <i>Females<\/i>\n    <\/p>\n<p>\n      Advise females of reproductive potential of the potential risk to a<br \/>\n      fetus and to use effective contraception during treatment and for 6<br \/>\n      months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i>\n    <\/p>\n<p>\n      Advise male patients with female partners of reproductive potential or<br \/>\n      who are pregnant to use effective contraception during treatment and for<br \/>\n      3 months following the last dose of LYNPARZA and to not donate sperm<br \/>\n      during this time.\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014First-Line Maintenance <i>BRCA<\/i>m Advanced<br \/>\n      Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226510% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting<\/b><br \/>\n      for <b>SOLO-1 <\/b>were: nausea (77%), fatigue (67%), abdominal pain<br \/>\n      (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%),<br \/>\n      upper respiratory tract infection\/influenza\/ nasopharyngitis\/bronchitis<br \/>\n      (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%),<br \/>\n      neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI<br \/>\n      (13%), thrombocytopenia (11%), and stomatitis (11%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting for<br \/>\n      SOLO-1<\/b> were: decrease in hemoglobin (87%), increase in mean<br \/>\n      corpuscular volume (87%), decrease in leukocytes (70%), decrease in<br \/>\n      lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease<br \/>\n      in platelets (35%), and increase in serum creatinine (34%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting <\/b>for <b>SOLO-2<\/b><br \/>\n      were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%),<br \/>\n      vomiting (37%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI)\/influenza (36%), diarrhea (33%), arthralgia\/myalgia (30%),<br \/>\n      dysgeusia (27%), headache (26%), decreased appetite (22%), and<br \/>\n      stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19: <\/b>nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), decreased appetite<br \/>\n      (21%), and dyspepsia (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study<br \/>\n      19<\/b>) were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Advanced g<i>BRCA<\/i>m Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy <\/b>(pooled from 6 studies) were:<br \/>\n      fatigue\/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%),<br \/>\n      diarrhea (31%), nasopharyngitis\/upper respiratory tract infection (URI)<br \/>\n      (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and<br \/>\n      arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer <\/b>(pooled<br \/>\n      from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular<br \/>\n      volume elevation (57%), decrease in lymphocytes (56%), increase in serum<br \/>\n      creatinine (30%), decrease in platelets (30%), and decrease in absolute<br \/>\n      neutrophil count (25%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014g<i>BRCA<\/i>m, HER2-negative Metastatic Breast<br \/>\n      Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in <b>OlympiAD<\/b><br \/>\n      were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%),<br \/>\n      vomiting (30%), neutropenia (27%), respiratory tract infection (27%),<br \/>\n      leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in <b>OlympiAD<br \/>\n      <\/b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%),<br \/>\n      decrease in leukocytes (71%), increase in mean corpuscular volume (71%),<br \/>\n      decrease in absolute neutrophil count (46%), and decrease in platelets<br \/>\n      (33%).\n    <\/p>\n<p>\n      <b>DRUG INTERACTIONS<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>USE IN SPECIFIC POPULATIONS<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild or moderate hepatic impairment<br \/>\n      (Child-Pugh classification A and B). There are no data in patients with<br \/>\n      severe hepatic impairment (Child-Pugh classification C).\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min) but patients<br \/>\n      should be monitored closely for toxicity. In patients with moderate<br \/>\n      renal impairment (CLcr=31-50 mL\/min), reduce the dose to 200 mg twice<br \/>\n      daily. There are no data in patients with severe renal impairment or<br \/>\n      end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>INDICATIONS<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      <b>First-Line Maintenance <i>BRCA<\/i>m Advanced Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with deleterious or<br \/>\n      suspected deleterious germline or somatic <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m<i><br \/>\n      <\/i>or s<i>BRCA<\/i>m) advanced epithelial ovarian, fallopian tube or<br \/>\n      primary peritoneal cancer who are in complete or partial response to<br \/>\n      first-line platinum-based chemotherapy. Select patients with g<i>BRCA<\/i>m<br \/>\n      advanced epithelial ovarian, fallopian tube or primary peritoneal cancer<br \/>\n      for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Maintenance Recurrent Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      <b>Advanced g<i>BRCA<\/i>m Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline <i>BRCA-<\/i>mutated (g<i>BRCA<\/i>m) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>g<i>BRCA<\/i>m, HER2-negative Metastatic Breast Cancer<\/b>\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious g<i>BRCA<\/i>m<i>, <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have been treated with chemotherapy in the neoadjuvant,<br \/>\n      adjuvant or metastatic setting. Patients with hormone receptor<br \/>\n      (HR)-positive breast cancer should have been treated with a prior<br \/>\n      endocrine therapy or be considered inappropriate for endocrine therapy.<br \/>\n      Select patients for therapy based on an FDA-approved companion<br \/>\n      diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Please see complete <\/b><br \/>\n<a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b>, including Patient Information (Medication Guide).<\/b>\n    <\/p>\n<p>\n      <b>About OlympiAD<\/b>\n    <\/p>\n<p>\n      OlympiAD was a global, randomized, open-label, multi-center Phase 3<br \/>\n      trial of 302 patients, assessing the efficacy and safety of&nbsp;LYNPARZA<i>&nbsp;<\/i>tablets<br \/>\n      (300 mg twice daily) compared to the physician\u2019s choice of chemotherapy<br \/>\n      (capecitabine, eribulin or vinorelbine). Two-hundred and five patients<br \/>\n      were randomized to receive&nbsp;LYNPARZA<i>&nbsp;<\/i>and<i>&nbsp;<\/i>97<br \/>\n      patients were randomized to receive chemotherapy. Patients in the<br \/>\n      OlympiAD trial had germline&nbsp;<i>BRCA<\/i>1 and\/or <i>BRCA<\/i>2-mutated,<br \/>\n      HER2-negative (hormone receptor-positive [HR+] or triple-negative)<br \/>\n      breast cancer and received&nbsp;LYNPARZA<i>&nbsp;<\/i>for treatment in<br \/>\n      the metastatic setting.\n    <\/p>\n<p>\n      Prior to enrollment, all patients were treated with an anthracycline<br \/>\n      (unless it was contraindicated) and a taxane chemotherapy in the<br \/>\n      neoadjuvant, adjuvant or metastatic setting. Patients with metastatic<br \/>\n      breast cancer (71% of patients) had received no more than two previous<br \/>\n      chemotherapy treatments for metastatic disease. Patients with<br \/>\n      HR-positive breast cancer had received at least one endocrine (hormonal)<br \/>\n      therapy (in the adjuvant or metastatic setting) and had disease<br \/>\n      progression during therapy, unless they had disease for which endocrine<br \/>\n      therapy was considered inappropriate. Previous treatment with platinum<br \/>\n      chemotherapy in the neoadjuvant, adjuvant or metastatic setting was<br \/>\n      allowed (28% of patients).\n    <\/p>\n<p>\n      The most common adverse reactions (\u226520%) in the OlympiAD trial of<br \/>\n      patients who received LYNPARZA were nausea (58%), anemia (40%), fatigue<br \/>\n      (including asthenia) (37%), vomiting (30%), neutropenia (27%),<br \/>\n      respiratory tract infection (27%), leukopenia (25%), diarrhea (21%) and<br \/>\n      headache (20%). The percentage of patients who discontinued treatment in<br \/>\n      the LYNPARZA arm was five percent versus eight percent in the<br \/>\n      chemotherapy arm.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a first-in-class PARP inhibitor and the first targeted<br \/>\n      treatment to potentially exploit DNA damage response (DDR) pathway<br \/>\n      deficiencies, such as <i>BRCA<\/i> mutations, to preferentially kill<br \/>\n      cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of<br \/>\n      PARP bound to DNA single-strand breaks, stalling of replication forks,<br \/>\n      their collapse and the generation of DNA double-strand breaks and cancer<br \/>\n      cell death. LYNPARZA is being tested in a range of tumor types with<br \/>\n      defects and dependencies in the DDR.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, has a broad and advanced clinical trial<br \/>\n      development program, and AstraZeneca and Merck are working together to<br \/>\n      understand how it may affect multiple PARP-dependent tumors as a<br \/>\n      monotherapy and in combination across multiple cancer types.\n    <\/p>\n<p>\n      <b>About Advanced Breast Cancer<\/b>\n    <\/p>\n<p>\n      Advanced\/metastatic breast cancer refers to Stage III tumors that cannot<br \/>\n      be fully excised by surgery and Stage IV breast cancer. Stage III<br \/>\n      disease may also be referred to as locally-advanced breast cancer, while<br \/>\n      metastatic disease is the most-advanced stage of breast cancer (Stage<br \/>\n      IV) and occurs when cancer cells have spread beyond the initial tumor<br \/>\n      site to other organs of the body outside the breast. Since there is no<br \/>\n      cure for the disease, the goal of current treatment is to delay disease<br \/>\n      worsening or death.\n    <\/p>\n<p>\n      In 2018, there were an estimated 2.1 million new cases of breast cancer<br \/>\n      worldwide \u2013 one in four cancer cases among women (24.2%). In Europe the<br \/>\n      estimated five-year prevalence of breast cancer in 2018 was 2,054,887<br \/>\n      cases. Approximately 30 percent of women who are diagnosed with early<br \/>\n      breast cancer will go on to develop advanced disease.\n    <\/p>\n<p>\n      <b>About <i>BRCA<\/i> Mutations<\/b>\n    <\/p>\n<p>\n      Breast cancer susceptibility gene 1\/2 (<i>BRCA<\/i>1 and <i>BRCA<\/i>2)<br \/>\n      are human genes that produce proteins responsible for repairing damaged<br \/>\n      DNA and play an important role in maintaining the genetic stability of<br \/>\n      cells. When either of these genes is mutated, or altered, such that its<br \/>\n      protein product either is not made or does not function correctly, DNA<br \/>\n      damage may not be repaired properly, and cells become unstable. As a<br \/>\n      result, cells are more likely to develop additional genetic alterations<br \/>\n      that can lead to cancer.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck, known as MSD outside the United<br \/>\n      States and Canada, announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a><br \/>\n<span class=\"bwuline\">)<\/span>.\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media Contacts:     <\/p>\n<p>       Pamela Eisele<br \/>(267) 305-3558     <\/p>\n<p>       Michael Close<br \/>(267) 305-1211     <\/p>\n<p>       Investor Contacts:     <\/p>\n<p>       Teri Loxam<br \/>(908) 740-1986     <\/p>\n<p>       Michael DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Commission has approved LYNPARZA as a monotherapy for the treatment of adult patients with germline BRCA 1\/2-mutations (g BRCA m), and who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Under the licensed indication, patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless they were unsuitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy or be considered unsuitable for endocrine therapy. Dave Fredrickson, executive vice president, oncology, AstraZeneca, said, \u201cWith this approval, LYNPARZA provides patients throughout the EU with a targeted and oral chemotherapy-free treatment option for a difficult-to-treat cancer. It also reinforces the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289,56],"class_list":["post-746057","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Commission has approved LYNPARZA as a monotherapy for the treatment of adult patients with germline BRCA 1\/2-mutations (g BRCA m), and who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Under the licensed indication, patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless they were unsuitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy or be considered unsuitable for endocrine therapy. Dave Fredrickson, executive vice president, oncology, AstraZeneca, said, \u201cWith this approval, LYNPARZA provides patients throughout the EU with a targeted and oral chemotherapy-free treatment option for a difficult-to-treat cancer. It also reinforces the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\\\/\",\"name\":\"LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-04-10T05:45:00+00:00\",\"dateModified\":\"2025-05-12T12:58:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer - Merck.com","og_description":"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the European Commission has approved LYNPARZA as a monotherapy for the treatment of adult patients with germline BRCA 1\/2-mutations (g BRCA m), and who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Under the licensed indication, patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless they were unsuitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy or be considered unsuitable for endocrine therapy. Dave Fredrickson, executive vice president, oncology, AstraZeneca, said, \u201cWith this approval, LYNPARZA provides patients throughout the EU with a targeted and oral chemotherapy-free treatment option for a difficult-to-treat cancer. It also reinforces the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:13+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/","name":"LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-04-10T05:45:00+00:00","dateModified":"2025-05-12T12:58:13+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-negative-advanced-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"LYNPARZA\u00ae (olaparib) Approved in EU for the Treatment of Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"87f4aecd-de87-4f05-8c7b-bd6d3a6624db","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/LYNPARZA-olaparib-Approved-in-EU-for-the-Treatment-of-Germline-BRCA-Mutated-HER2-Negative-Advanced-Breast-Cancer-2019.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746057\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746057"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}